E75.0

Clinical Causes: Genetic mutations leading to deficiency of specific enzymes (Hexosaminidase A in Tay-Sachs, combined Hexosaminidase A and B in Sandhoff disease). Inheritance pattern is autosomal recessive, meaning both parents must pass on the faulty gene for a child to be affected. Mutations disrupt the body's ability to produce functioning enzymes necessary for breaking down GM2 gangliosides.

Key Symptoms: Progressive loss of motor skills and muscle weakness. Delayed development or regression of acquired skills. Increased startle response and exaggerated reactions to stimuli. Vision and hearing difficulties as the disorder progresses. Spasticity, seizures, and difficulty swallowing. Cherry-red spot observed in the retina during eye examinations. Cognitive decline and intellectual disability. In advanced stages, paralysis and profound dementia may occur.

Diagnosis Path: Detailed medical and family history to assess genetic risks. Physical and neurological examinations to observe characteristic signs. Laboratory tests measuring enzyme activity levels, particularly Hexosaminidase A (and B in some cases) in blood or tissue samples. Genetic testing to identify specific mutations in the HEXA or HEXB genes. Imaging studies such as MRI scans to detect brain atrophy or other neurological changes. Ophthalmological exams revealing a cherry-red spot in the retina.

Treatment Protocols: Supportive care to address nutritional needs, physical therapy to maintain mobility, and occupational therapy for daily living skills. Medications for symptom relief such as anticonvulsants for seizures, spasticity management, and pain control. Genetic counseling offered to affected families concerned about recurrence risks. Emerging research into enzyme replacement and gene therapy offers hope for potential future treatments. Palliative care approaches to provide comfort during advanced stages of the disease.